Human papillomavirus type 16 E6, E7, and L2 antigens (HPV16 E6/E7/L2)

Human papillomavirus type 16 (HPV16) E6, E7, and L2 are viral proteins that serve as critical targets for both prophylactic and therapeutic interventions against HPV-related malignancies [1, 5]. E6 and E7 are early-expressed oncoproteins essential for the induction and maintenance of the malignant phenotype; E6 facilitates the degradation of the tumor suppressor p53, while E7 inactivates the retinoblastoma protein (pRb), collectively leading to cell cycle deregulation and evasion of apoptosis [6, 15, 18]. L2 is a minor capsid protein involved in viral entry and endosomal escape, making it a target for inducing cross-neutralizing antibodies [1, 2]. Therapeutic strategies, such as the TA-CIN fusion protein vaccine and various DNA-based platforms like pNGVL4a-CRTE6E7L2, aim to stimulate CD4+ and CD8+ T-cell responses against E6 and E7 to eliminate infected cells and tumors [3, 4, 5]. These antigens are central to the treatment and prevention of cervical, oropharyngeal, and other anogenital cancers [6, 10]. Clinical trials have explored these targets in the context of precancerous lesions like cervical intraepithelial neoplasia (CIN) and established carcinomas to provide both therapeutic clearance and broad protection [5, 13, 21].

Other names

HPV16 oncoproteins (E6 and E7)HPV16 minor capsid protein (L2)HPV16 early proteins E6 and E7HPV16 late protein L2HPV16 L2/E6/E7 fusion protein

Induction of antigen-specific CD4+ and CD8+ T-cell responses to eliminate infected cells; induction of L2-specific neutralizing antibodies to prevent viral entry; and indirect restoration of p53 and pRb tumor suppressor pathways through the clearance of cells expressing these viral oncoproteins [1, 2, 6].